Joel Beatty's Stock Ratings

Baird Analyst

Joel Beatty is an analyst at Baird. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 05/17/2024

Overall Average Return

25.7%

Smart Score

71.4%

Overall Average Return Percentile

84th

Number of Ratings

62
Buy NowGet Alert
05/17/2024BMRNBuy Now
Biomarin Pharmaceutical
$77.34-6.9%$104 → $72DowngradeOutperform → NeutralGet Alert
05/15/2024CLDIBuy Now
Calidi Biotherapeutics
$0.24747.46%$4.5 → $2MaintainsOutperformGet Alert
05/09/2024ACADBuy Now
ACADIA Pharmaceuticals
$14.8388.81%$31 → $28MaintainsOutperformGet Alert
05/07/2024AXSMBuy Now
Axsome Therapeutics
$78.1243.37%$108 → $112MaintainsOutperformGet Alert
05/01/2024PRAXBuy Now
Praxis Precision Medicine
$44.77161.34% → $117Initiates → OutperformGet Alert
05/01/2024LBPHBuy Now
Longboard Pharmaceuticals
$20.4076.47% → $36Initiates → OutperformGet Alert
04/30/2024GERNBuy Now
Geron
$3.7220.97% → $4.5DowngradeOutperform → NeutralGet Alert
04/17/2024ITCIBuy Now
Intra-Cellular Therapies
$67.0053.73%$83 → $103MaintainsOutperformGet Alert
04/11/2024NRIXBuy Now
Nurix Therapeutics
$15.9456.84%$24 → $25MaintainsOutperformGet Alert
04/11/2024AMLXBuy Now
Amylyx Pharma
$1.7967.6%$4 → $3MaintainsNeutralGet Alert
03/21/2024CLDIBuy Now
Calidi Biotherapeutics
$0.241806.78%$9 → $4.5MaintainsOutperformGet Alert
03/19/2024LPTXBuy Now
Leap Therapeutics
$2.51258.57%$11 → $9MaintainsOutperformGet Alert
03/19/2024ALKSBuy Now
Alkermes
$24.3452.01% → $37Initiates → OutperformGet Alert
03/19/2024AXSMBuy Now
Axsome Therapeutics
$78.1238.25% → $108Initiates → OutperformGet Alert
03/12/2024ACADBuy Now
ACADIA Pharmaceuticals
$14.83109.04%$40 → $31MaintainsOutperformGet Alert
03/11/2024AMLXBuy Now
Amylyx Pharma
$1.79123.46%$37 → $4DowngradeOutperform → NeutralGet Alert
03/01/2024ARGXBuy Now
argenx
$356.6637.39%$505 → $490MaintainsOutperformGet Alert
02/26/2024COGTBuy Now
Cogent Biosciences
$7.703.92%$14 → $8DowngradeOutperform → NeutralGet Alert
01/30/2024RAREBuy Now
Ultragenyx Pharmaceutical
$40.5867.57%$57 → $68MaintainsOutperformGet Alert
01/30/2024BMRNBuy Now
Biomarin Pharmaceutical
$77.3434.47%$127 → $104MaintainsOutperformGet Alert
01/30/2024ELFBuy Now
e.l.f. Beauty
$159.5115.98% → $185Initiates → NeutralGet Alert
01/30/2024ACADBuy Now
ACADIA Pharmaceuticals
$14.83169.72% → $40Initiates → OutperformGet Alert
01/16/2024AMAMBuy Now
Ambrx Biopharma
—— → $28DowngradeOutperform → NeutralGet Alert
01/03/2024AMLXBuy Now
Amylyx Pharma
$1.791967.04% → $37Initiates → OutperformGet Alert
01/03/2024JAZZBuy Now
Jazz Pharmaceuticals
$106.9749.57% → $160Initiates → OutperformGet Alert
01/03/2024ITCIBuy Now
Intra-Cellular Therapies
$67.0023.88% → $83Initiates → OutperformGet Alert
10/09/2023CLDIBuy Now
Calidi Biotherapeutics
$0.243713.56% → $9Initiates → OutperformGet Alert
09/08/2023VAXXBuy Now
Vaxxinity
$0.088313.46% → $7Initiates → OutperformGet Alert
08/28/2023IMMPBuy Now
Immutep
$3.39106.52% → $7ReiteratesOutperform → OutperformGet Alert
08/15/2023LPTXBuy Now
Leap Therapeutics
$2.51696.81%$30 → $20MaintainsOutperformGet Alert

Recent Analyst Stock Rating News

Walmart To Rally Over 17%? Here Are 10 Top Analyst Forecasts For Friday
Critical Insights From Praxis Precision Medicine Analyst Ratings: What You Need To Know
Key Takeaways From Nurix Therapeutics Analyst Ratings
Breaking Down argenx: 12 Analysts Share Their Views
Breaking Down Amylyx Pharma: 9 Analysts Share Their Views
Analyst Ratings For Intra-Cellular Therapies
7 Analysts Assess Alkermes: What You Need To Know
ACADIA Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (25 Ratings)
Peeling Back The Layers: Exploring Axsome Therapeutics Through Analyst Insights
Deep Dive Into Biomarin Pharmaceutical Stock: Analyst Perspectives (8 Ratings)
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.
Get Started for Free